Influenza is a viral infection that attacks the respiratory system. It can cause mild to severe illness, and at times can lead to death.
The antiviral drug oseltamivir can reduce
influenza infections and prevent deaths in a cost-saving manner under
most pandemic scenarios, indicates a new study.
‘The antiviral drug oseltamivir can reduce influenza infections and prevent deaths in a cost-saving manner under most pandemic scenarios.’
Investigators' analyses of phase II clinical data and information
from a previous influenza outbreak revealed that oseltamivir 75 mg
relative to no treatment was effective and affordable under all
scenarios. Oseltamivir 150 mg relative to 75 mg was not cost effective
in low transmissibility scenarios but was cost saving in high
"We used influenza as the critical exemplar for us to test the
concept that interdisciplinary pharmacometrics can be applied where the
pharmacokinetics/pharmacodynamics, clinical, or epidemiological
endpoints of interest can eventually be linked to health economic value"
said Prof. Carl Kirkpatrick co-author of the British Journal of Clinical Pharmacology
"This approach - which we have called 'pharmacology to the payer' -
can be applied across all disease areas and should facilitate greater
dialogue between industry, regulators, payers, and patients earlier in
the drug development process," added co-author Craig Rayner.